Micro ribonucleic acids (miRNAs) are a cluster of small non‐coding RNA molecules predicted to regulate more than 30% of coding messenger (m)RNAs in the human genome and proven to be essential in developmental and pathological processes. The miR‐182 gene was first found to be abundantly expressed in sensory organs and regulates the development of the retina and inner ear. Further studies revealed its roles in osteogenesis and T cell differentiation. In addition, the involvement of miR‐182 in cancer initiation and progression has recently been uncovered by a growing body of evidence, the majority of which supports its promoting effects in cell proliferation, angiogenesis, and invasion, as well as distant metastasis of various cancer types. Clinical analyses demonstrated the link of miR‐182 expression to poor prognosis in cancer patients. Mechanistically, multiple downstream genes including missing‐in‐metastasis, microphthalm‐associated transcription factor, FoxO1, cylindromatiosis, and others, can be targeted by miR‐182 and mediate its roles in cancer. miR‐182 is also interconnected with prominent cancer‐related signaling pathways, such as transforming growth factor beta and nuclear factor kappa beta. Interestingly, it was shown that in vivo targeting of miR‐182 prevented liver metastasis of melanoma. miR‐182 is emerging as an important regulator of malignancies, which warrants further study to establish the application potential of miR‐182 in cancer diagnosis and treatment.